<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Selected hormonal contraceptives: Oral contraceptives (birth control pills) and other delivery methods</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Selected hormonal contraceptives: Oral contraceptives (birth control pills) and other delivery methods</h1>
<div class="graphic"><div class="figure"><div class="ttl">Selected hormonal contraceptives: Oral contraceptives (birth control pills) and other delivery methods</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="20%"></colgroup> <colgroup width="40%"></colgroup> <tbody> <tr class="border_bottom_thick"> <td class="subtitle1">Progestin (mg)<sup>*</sup></td> <td class="subtitle1">Estrogen (micrograms)</td> <td class="subtitle1">United States brand name</td> <td class="subtitle1">Notes</td> </tr> <tr> <td class="subtitle2_left_white" colspan="4">Monophasic combinations</td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent1">Drospirenone (3)</td> <td>Ethinyl estradiol (20)</td> <td> <ul> <li>Beyaz</li> <li>Jasmiel</li> <li>Lo-Zumandimine</li> <li>Loryna</li> <li>Nikki</li> <li>Vestura</li> <li>Yaz</li> </ul> </td> <td> <p>Also approved for acne and premenstrual dysphoric disorder.</p> <p>In patients with conditions requiring chronic therapy with medications that may increase potassium, monitor serum potassium during the first treatment cycle and periodically thereafter if patient begins medication or develops a condition that increases risk for hyperkalemia.</p> Packaged as active tablets for 24 days and placebo for 4 days; except Beyaz, which contains 451 mcg of levomefolate per tablet (24 active tablets and 4 levomefolate tablets).</td> </tr> <tr> <td class="indent1">Levonorgestrel (0.09)</td> <td>Ethinyl estradiol (20)</td> <td> <ul> <li>Amethyst</li> <li>Dolishale</li> </ul> </td> <td> </td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent1">Levonorgestrel (0.1)</td> <td>Ethinyl estradiol (20)</td> <td> <ul> <li>Afirmelle</li> <li>Aubra EQ</li> <li>Aviane</li> <li>Balcoltra</li> <li>Delyla</li> <li>Falmina</li> <li>Joyeaux</li> <li>Lessina</li> <li>Lutera</li> <li>Sronyx</li> <li>Tyblume</li> <li>Vienva</li> </ul> </td> <td>Packaged as active tablets for 21 days and placebo for 7 days.</td> </tr> <tr> <td class="indent1" rowspan="3">Norethindrone acetate (1)</td> <td rowspan="3">Ethinyl estradiol (20)</td> <td class="border_bottom_thick"> <ul> <li>Aurovela 24 FE</li> <li>Blisovi 24 Fe</li> <li>Charlotte 24 Fe chewable tablets</li> <li>Finzala chewable tablets</li> <li>Gemmily capsules</li> <li>Hailey 24 Fe</li> <li>Junel Fe 24</li> <li>Larin 24 Fe</li> <li>Merzee capsules</li> <li>Mibelas 24 Fe chewable tablets</li> <li>Microgestin 24 Fe</li> <li>Minastrin 24 Fe chewable tablets</li> <li>Tarina 24 Fe</li> <li>Taysofy capsules</li> <li>Taytulla capsules</li> </ul> </td> <td class="border_bottom_thick">Packaged as active pills for 24 days and ferrous fumarate for 4 days.</td> </tr> <tr class="border_bottom_thick"> <td> <ul> <li>Aurovela FE 1/20</li> <li>Blisovi FE 1/20</li> <li>Hailey FE 1/20</li> <li>Junel FE 1/20</li> <li>Larin Fe 1/20</li> <li>Loestrin Fe 1/20</li> <li>Microgestin FE 1/20</li> <li>Tarina FE 1/20 EQ</li> </ul> </td> <td>Packaged as active tablets for 21 days and ferrous fumarate for 7 days.</td> </tr> <tr> <td> <ul> <li>Aurovela 1/20</li> <li>Junel 1/20</li> <li>Larin 1/20</li> <li>Loestrin 1/20</li> <li>Microgestin 1/20</li> </ul> </td> <td>Packaged as active tablets for 21 days (does not contain iron).</td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent1">Norethindrone (0.8)</td> <td>Ethinyl estradiol (25)</td> <td> <ul> <li>Kaitlib Fe chewable tablets</li> <li>Layolis FE chewable tablets</li> </ul> </td> <td>Packaged as active tablets for 24 days and ferrous fumarate for 4 days.</td> </tr> <tr> <td class="indent1">Desogestrel (0.15)</td> <td>Ethinyl estradiol (30)</td> <td> <ul> <li>Apri</li> <li>Cyred</li> <li>Cyred EQ</li> <li>Enskyce</li> <li>Isibloom</li> <li>Juleber</li> <li>Kalliga</li> <li>Reclipsen</li> </ul> </td> <td>Packaged as active tablets for 21 days and placebo for 7 days.</td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent1">Drospirenone (3)</td> <td>Ethinyl estradiol (30)</td> <td> <ul> <li>Ocella</li> <li>Safyral</li> <li>Syeda</li> <li>Tydemy</li> <li>Yasmin</li> <li>Zumandimine</li> </ul> </td> <td> <p>In patients with conditions requiring chronic therapy with medications that may increase potassium, monitor serum potassium during the first treatment cycle and periodically thereafter if patient begins medication or develops a condition that increases risk for hyperkalemia.</p> Packaged as active tablets for 21 days and placebo for 7 days; except Safyral and Tydemy, which contain 451 mcg of levomefolate per tablet (21 active tablets and 7 levomefolate tablets).</td> </tr> <tr> <td class="indent1">Levonorgestrel (0.15)</td> <td>Ethinyl estradiol (30)</td> <td> <ul> <li>Altavera</li> <li>Ayuna</li> <li>Chateal EQ</li> <li>Kurvelo</li> <li>Levora 0.15/30</li> <li>Marlissa</li> <li>Portia-28</li> </ul> </td> <td>Packaged as active tablets for 21 days and placebo for 7 days.</td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent1" rowspan="2">Norethindrone acetate (1.5)</td> <td rowspan="2">Ethinyl estradiol (30)</td> <td class="border_bottom_thick"> <ul> <li>Aurovela Fe 1.5/30</li> <li>Blisovi Fe 1.5/30</li> <li>Junel FE 1.5/30</li> <li>Hailey FE 1.5/30</li> <li>Larin Fe 1.5/30</li> <li>Loestrin Fe 1.5/30</li> <li>Microgestin FE 1.5/30</li> </ul> </td> <td class="border_bottom_thick">Packaged as active tablets for 21 days and ferrous fumarate for 7 days.</td> </tr> <tr class="highlight_lght_gray_text"> <td> <ul> <li>Aurovela 1.5/30</li> <li>Junel 1.5/30</li> <li>Hailey 1.5/30</li> <li>Larin 1.5/30</li> <li>Loestrin 1.5/30</li> <li>Microgestin 1.5/30</li> </ul> </td> <td>Packaged as active tablets for 21 days (does not contain iron).</td> </tr> <tr> <td class="indent1">Norgestrel (0.3)<sup>¶</sup></td> <td>Ethinyl estradiol (30)</td> <td> <ul> <li>Cryselle-28</li> <li>Elinest</li> <li>Low-Ogestrel</li> <li>Turqoz</li> </ul> </td> <td>Packaged as active tablets for 21 days and placebo for 7 days.</td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent1">Ethynodiol diacetate (1)</td> <td>Ethinyl estradiol (35)</td> <td> <ul> <li>Kelnor 1/35</li> <li>Zovia 1/35</li> </ul> </td> <td>Packaged as active tablets for 21 days and placebo for 7 days.</td> </tr> <tr> <td class="indent1" rowspan="2">Norethindrone (0.4)</td> <td rowspan="2">Ethinyl estradiol (35)</td> <td class="border_bottom_thick"> <ul> <li>Balziva</li> <li>Briellyn</li> <li>Philith</li> <li>Vyfemla</li> </ul> </td> <td class="border_bottom_thick">Packaged as active tablets for 21 days and placebo for 7 days.</td> </tr> <tr> <td> <ul> <li>Wymzya Fe chewable tablets</li> </ul> </td> <td>Packaged as active tablets for 21 days and ferrous fumarate for 7 days.</td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent1">Norethindrone (0.5)</td> <td>Ethinyl estradiol (35)</td> <td> <ul> <li>Necon 0.5/35 (28)</li> <li>Nortrel 0.5/35 (28)</li> <li>Wera</li> </ul> </td> <td>Packaged as active tablets for 21 days and placebo for 7 days.</td> </tr> <tr> <td class="indent1">Norethindrone (1)</td> <td>Ethinyl estradiol (35)</td> <td> <ul> <li>Alyacen 1/35</li> <li>Dasetta 1/35</li> <li>Nortrel 1/35 (28)</li> <li>Nylia 1/35</li> <li>Pirmella 1/35</li> </ul> </td> <td> <p>Packaged as active tablets for 21 days and placebo for 7 days.</p> Nortrel 1/35 is also available as a 21-day regimen (packaged without placebo).</td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent1">Norgestimate (0.25)</td> <td>Ethinyl estradiol (35)</td> <td> <ul> <li>Estarylla</li> <li>Femynor</li> <li>Mili</li> <li>Mono-Linyah</li> <li>Nymyo</li> <li>Sprintec 28</li> <li>VyLibra</li> </ul> </td> <td>Packaged as active tablets for 21 days and placebo for 7 days.</td> </tr> <tr> <td class="indent1">Cyproterone (2)</td> <td>Ethinyl estradiol (35)</td> <td> <ul> <li>Cleo-35</li> <li>Cyestra-35</li> <li>Diane-35</li> </ul> </td> <td> <p>Labeled approval in Canada is for treatment of acne; provides reliable contraception if taken as recommended for treatment of acne.</p> <p>Packaged as active tablets for 21 days.</p> Not available in the United States; Canadian product shown.</td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent1">Ethynodiol diacetate (1)</td> <td>Ethinyl estradiol (50)</td> <td> <ul> <li>Kelnor 1/50</li> </ul> </td> <td> <p>Packaged as active tablets for 21 days and placebo for 7 days.</p> <strong>NOTE: Pills containing 50 mcg of ethinyl estradiol are not indicated for routine contraceptive use because of increased risk of cardiovascular events compared with lower-dose oral contraceptive pills.</strong></td> </tr> <tr> <td class="indent1">Drospirenone (3)</td> <td> <p>Estetrol (14.2)</p> NOTE: Estetrol strength listed in <strong>milligrams (mg)</strong></td> <td> <ul> <li>Nextstellis</li> </ul> </td> <td> <p>Packaged as active tablets for 24 days and placebo for 4 days.</p> In patients with conditions requiring chronic therapy with medications that may increase potassium, monitor serum potassium during the first treatment cycle and periodically thereafter if patient begins medication or develops a condition that increases risk for hyperkalemia.</td> </tr> <tr class="border_bottom_thick highlight_lght_gray_text"> <td class="indent1">Nomegestrol acetate (2.5)</td> <td> <p>Estradiol (as hemihydrate) (1.5)</p> NOTE: Estradiol strength listed in <strong>milligrams (mg)</strong></td> <td> <ul> <li>Zoely</li> </ul> </td> <td> <p>Packaged as active tablets for 24 days and placebo for 4 days.</p> Not available in the United States; United Kingdom and European Union product shown.</td> </tr> <tr> <td class="subtitle2_left_white" colspan="4">Multiphasic combinations</td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent1">Dienogest (0,2,3,0)</td> <td> <p>Estradiol valerate (3,2,2,1)</p> NOTE: Estradiol strength listed in <strong>milligrams (mg)</strong></td> <td> <ul> <li>Natazia</li> </ul> </td> <td>Packaged as active tablets for 26 days and placebo for 2 days.</td> </tr> <tr> <td class="indent1">Norethindrone acetate (1,0)</td> <td>Ethinyl estradiol (10,10)</td> <td> <ul> <li>Lo Loestrin Fe</li> </ul> </td> <td>Packaged as active tablets for 26 days and ferrous fumarate for 2 days.</td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent1">Desogestrel (0.15,0,0)</td> <td>Ethinyl estradiol (20,0,10)</td> <td> <ul> <li>Azurette</li> <li>Kariva</li> <li>Mircette</li> <li>Pimtrea</li> <li>Simliya</li> <li>Viorele</li> <li>Volnea</li> </ul> </td> <td>Packaged as active tablets for 26 days and placebo for 2 days.</td> </tr> <tr> <td class="indent1">Norethindrone acetate (1,1,1)</td> <td>Ethinyl estradiol (20,30,35)</td> <td> <ul> <li>Tilia Fe</li> <li>Tri-Legest Fe</li> </ul> </td> <td> <p>Also approved for acne.</p> Packaged as active tablets for 21 days and ferrous fumarate for 7 days.</td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent1">Norgestimate (0.18,0.215,0.25)</td> <td>Ethinyl estradiol (25,25,25)</td> <td> <ul> <li>Tri-Lo-Estarylla</li> <li>Tri-Lo-Marzia</li> <li>Tri-Lo-Mili</li> <li>Tri-Lo-Sprintec</li> <li>Tri-Vylibra Lo</li> </ul> </td> <td>Packaged as active tablets for 21 days and placebo for 7 days.</td> </tr> <tr> <td class="indent1">Desogestrel (0.1,0.125,0.15)</td> <td>Ethinyl estradiol (25,25,25)</td> <td> <ul> <li>Velivet</li> </ul> </td> <td>Packaged as active tablets for 21 days and placebo for 7 days.</td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent1">Levonorgestrel (0.05,0.075,0.125)</td> <td>Ethinyl estradiol (30,40,30)</td> <td> <ul> <li>Enpresse-28</li> <li>Levonest</li> <li>Trivora (28)</li> </ul> </td> <td>Packaged as active tablets for 21 days and placebo for 7 days.</td> </tr> <tr> <td class="indent1">Norgestimate (0.18,0.215,0.25)</td> <td>Ethinyl estradiol (35,35,35)</td> <td> <ul> <li>Tri-Estarylla</li> <li>Tri-Linyah</li> <li>Tri-Mili</li> <li>Tri-Nymyo</li> <li>Tri-Sprintec</li> <li>Tri-VyLibra</li> </ul> </td> <td> <p>Also approved for acne.</p> Packaged as active tablets for 21 days and placebo for 7 days.</td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent1">Norethindrone (0.5,0.75,1)</td> <td>Ethinyl estradiol (35,35,35)</td> <td> <ul> <li>Alyacen 7/7/7</li> <li>Dasetta 7/7/7</li> <li>Nortrel 7/7/7</li> <li>Nylia 7/7/7</li> <li>Pirmella 7/7/7</li> </ul> </td> <td>Packaged as active tablets for 21 days and placebo for 7 days.</td> </tr> <tr class="border_bottom_thick"> <td class="indent1">Norethindrone (0.5,1,0.5)</td> <td>Ethinyl estradiol (35,35,35)</td> <td> <ul> <li>Aranelle</li> <li>Leena</li> </ul> </td> <td>Packaged as active tablets for 21 days and placebo for 7 days.</td> </tr> <tr> <td class="subtitle2_left_white" colspan="4">Extended combinations (91-day regimens)</td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent1">Levonorgestrel (0.1,0)</td> <td>Ethinyl estradiol (20,10)</td> <td> <ul> <li>Camrese Lo</li> <li>LoJaimiess</li> <li>LoSeasonique</li> </ul> </td> <td>Packaged as a 91-day regimen: 84 days of the combination and 7 days of 10 mcg ethinyl estradiol only.</td> </tr> <tr> <td class="indent1">Levonorgestrel (0.15,0.15,0.15,0)</td> <td>Ethinyl estradiol (20,25,30,10)</td> <td> <ul> <li>Fayosim</li> <li>Quartette</li> <li>Rivelsa</li> </ul> </td> <td>Packaged as a 91-day regimen: 84 days of the combination and 7 days of 10 mcg ethinyl estradiol only.</td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent1">Levonorgestrel (0.15,0)</td> <td>Ethinyl estradiol (30,10)</td> <td> <ul> <li>Amethia</li> <li>Ashlyna</li> <li>Camrese</li> <li>Daysee</li> <li>Jaimiess</li> <li>Seasonique</li> <li>Simpesse</li> </ul> </td> <td>Packaged as a 91-day regimen: 84 days of the combination and 7 days of 10 mcg ethinyl estradiol only.</td> </tr> <tr class="border_bottom_thick"> <td class="indent1">Levonorgestrel (0.15)</td> <td>Ethinyl estradiol (30)</td> <td> <ul> <li>Introvale</li> <li>Iclevia</li> <li>Jolessa</li> <li>Setlakin</li> </ul> </td> <td>Packaged as a 91-day regimen: active tablets for 84 days and placebo for 7 days.</td> </tr> <tr> <td class="subtitle2_left_white" colspan="4">Continuous combinations</td> </tr> <tr class="border_bottom_thick"> <td class="indent1" colspan="4">May use any monophasic 21/7 combination (eg, Amethyst [levonorgestrel 0.09 mcg-ethinyl estradiol 20 mcg]) by taking active hormone pills for 28 or more days continuously. Any progestin may be used, and higher doses of ethinyl estradiol may be used in some women. Refer to UpToDate topic.</td> </tr> <tr> <td class="subtitle2_left_white" colspan="4">Progestin-only</td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent1">Norethindrone (0.35)</td> <td>None</td> <td> <ul> <li>Camila</li> <li>Deblitane</li> <li>Errin</li> <li>Heather</li> <li>Incassia</li> <li>Jencycla</li> <li>Lyleq</li> <li>Lyza</li> <li>Nora-BE</li> <li>Norlyroc</li> <li>Sharobel</li> </ul> </td> <td>Packaged as active tablets for 28 days.</td> </tr> <tr> <td class="indent1">Drospirenone (4)</td> <td>None</td> <td> <ul> <li>Slynd</li> </ul> </td> <td> <p>Packaged as active tablets for 24 days and placebo for 4 days.</p> In patients with conditions requiring chronic therapy with medications that may increase potassium, monitor serum potassium during the first treatment cycle and periodically thereafter if patient begins medication or develops a condition that increases risk for hyperkalemia.</td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent1">Norgestrel (0.075)</td> <td>None</td> <td> <ul> <li>Opill</li> </ul> </td> <td> <p>Packaged as active tablets for 28 days.</p> Approved for over-the-counter use in the United States.</td> </tr> <tr class="border_bottom_thick"> <td class="indent1">Desogestrel (0.075)</td> <td>None</td> <td> <ul> <li>Cerazette</li> <li>Cerelle</li> <li>Hana</li> <li>Lovima</li> <li>Zelleta</li> </ul> </td> <td> <p>Packaged as active tablets for 28 days.</p> Not available in the United States or Canada; United Kingdom product shown.</td> </tr> <tr> <td class="subtitle2_left_white" colspan="4">Transdermal patch, weekly</td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent1">Norelgestromin (releases 0.15 mg/day)</td> <td>Ethinyl estradiol (releases 35 mcg/day)</td> <td> <ul> <li>Xulane</li> <li>Zafemy</li> </ul> </td> <td> <p>May have diminished efficacy in women ≥90 kg.</p> <p>A new patch is applied every 7 days for 3 weeks followed by a patch-free week.</p> These products are therapeutically equivalent to Ortho Evra patch, which is no longer available in the United States.</td> </tr> <tr class="border_bottom_thick"> <td class="indent1">Levonorgestrel (releases 0.12 mg/day)</td> <td>Ethinyl estradiol (releases 30 mcg/day)</td> <td> <ul> <li>Twirla</li> </ul> </td> <td> <p>Contraindicated in women with BMI ≥30 kg/m<sup>2</sup> due to decreased efficacy and increased risk of VTE. Diminished efficacy was observed in women with BMI ≥25 kg/m<sup>2</sup>.</p> A new patch is applied every 7 days for 3 weeks followed by a patch-free week.</td> </tr> <tr> <td class="subtitle2_left_white" colspan="4">Vaginal ring, monthly</td> </tr> <tr class="highlight_lght_gray_text"> <td class="indent1">Etonogestrel (releases 0.12 mg/day)</td> <td>Ethinyl estradiol (releases 15 mcg/day)</td> <td> <ul> <li>NuvaRing</li> <li>EluRyng</li> <li>EnilloRing</li> <li>Haloette</li> </ul> </td> <td>Ring is inserted for 3 weeks followed by 1 week without ring in place. A new ring is inserted 7 days after the last was removed.</td> </tr> <tr> <td class="indent1">Segesterone (releases 0.15 mg/day)</td> <td>Ethinyl estradiol (releases 13 mcg/day)</td> <td> <ul> <li>Annovera</li> </ul> </td> <td>Ring is inserted for 3 weeks followed by 1 week without ring in place. The ring is then reinserted for the first 21 days of subsequent 28-day cycles. One system provides contraception for 13 28-day cycles (1 year). Not yet adequately evaluated in women with BMI &gt;29 kg/m<sup>2</sup>.</td> </tr> </tbody></table></div><div class="graphic_lgnd"><ul>
<li>Oral and IUD emergency contraceptive options are listed in a table that is available separately in UpToDate.</li>
<li>Generic (non-branded) products are also available for most combination oral contraceptives in the United States.</li>
<li>Descriptions are for US-available products unless noted otherwise. Consult local product information before use.</li>
</ul></div><div class="graphic_footnotes"><p>BMI: body mass index; Fe: contains iron; IUD: intrauterine device; VTE: venous thromboembolism.</p>
<p>* Different progestins are not equivalent on a milligram basis. Refer to the UpToDate overview of combined hormonal contraceptives for guidance on selection.</p>
¶ The progestin norgestrel contains two isomers; only levonorgestrel is bioactive. The amount of norgestrel in each tablet is twice the amount of levonorgestrel.</div><div class="graphic_reference">Adapted from:
<ol>
<li>The Medical Letter on Drugs and Therapeutics, October 8, 2018; Vol. 60 (1557): 161-168.</li>
<li>The Medical Letter on Drugs and Therapeutics, May 15, 2023; Vol. 65 (1676): 73-82.</li>
<li>Lexicomp online. Copyright © 1978-2024 by Lexicomp, Inc. All rights reserved.</li>
</ol></div><div id="graphicVersion">Graphic 69223 Version 56.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
